UCB

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the discovery and development of innovative medicines for severe diseases of the immune system and the central nervous system (CNS). The company has successfully transitioned from its industrial chemical roots to a pure-play biopharma leader, focusing on high-unmet-need areas such as epilepsy, Parkinson's disease, and various autoimmune conditions like psoriasis and myasthenia gravis. UCB's strategy is currently driven by a 'decade of growth' fueled by five key products: Bimzelx, Rystiggo, Zilbrysq, Fintepla, and Evenity. The company maintains a strong global presence, operating in approximately 40 countries and reaching over 3.1 million patients annually. UCB is known for its high R&D intensity, reinvesting nearly 25-30% of its revenue into its innovation pipeline.